Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIgAN: Targeted Therapy Based on Kidney Biopsy in IgA Nephropathy
2024-517861-18-00Phase 3Authorised
- Sponsor
- Fondazione Schena
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone, methylprednisolone, dapagliflozin, ramipril and losartan in IgA nephropathy (IgAN) (4 arms), sponsored by Fondazione Schena. Primary endpoints: Between-arms difference in proteinuria reduction within 4 months (ACIgAN), Between-arms difference in proteinuria reduction within 8 months among non-responders (ACIgAN) and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
prednisonemethylprednisolonedapagliflozinramiprillosartan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-517861-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517861-18-00.